Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Hiroki Sato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6994-1840; OpenAlex author ID A5026390892. Sources: OpenAlex.

Their work

Papers
17
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 17

  1. Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic c… Co-author DOI 10.1002/1878-0261.70011↗
  2. Common hepatic artery lymph node metastasis in pancreatic ductal adenocarcinoma: an analysis of actual survival. Co-author DOI 10.1016/j.gassur.2024.02.018↗
  3. Liquid Biopsy for Pancreatic Cancer by Serum Extracellular Vesicle-Encapsulated Long Noncoding RNA HEVEPA. Co-author DOI 10.1097/mpa.0000000000002315↗
  4. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Co-author DOI 10.1038/s41416-022-02106-9↗
  5. Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15020498↗
  6. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… Co-author PMID 37293171↗
  7. Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway. Co-author DOI 10.1007/s00535-021-01846-4↗
  8. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101533↗
  9. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  10. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Co-author DOI 10.3390/cancers14040868↗
  11. Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer. Co-author DOI 10.1002/acm2.13429↗
  12. Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model. Co-author DOI 10.1016/j.pan.2021.03.002↗
  13. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.700315↗
  14. Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profiling during the long-term postoperative c… Co-author DOI 10.1097/md.0000000000020564↗
  15. Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB. Co-author DOI 10.1055/a-1034-7700↗
  16. Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer. Co-author DOI 10.1055/a-0721-1747↗
  17. Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells. Co-author DOI 10.1111/cas.13064↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hidemasa Kawabata · 7 shared papers, 2018–2025 · strength 0.87
  2. Yusuke Mizukami · 7 shared papers, 2018–2025 · strength 0.87
  3. Norio Uemura · 5 shared papers, 2021–2023 · strength 0.80
  4. Hiromitsu Hayashi · 5 shared papers, 2021–2023 · strength 0.80
  5. Zhao Liu · 5 shared papers, 2021–2023 · strength 0.80
  6. Toshikatsu Okumura · 6 shared papers, 2018–2024 · strength 0.63
  7. Kazuki Matsumura · 4 shared papers, 2021–2023 · strength 0.60
  8. Mikihiro Fujiya · 5 shared papers, 2019–2024 · strength 0.56
  9. Kenji Takahashi · 3 shared papers, 2022–2025 · strength 0.52
  10. Tetsuhiro Okada · 5 shared papers, 2018–2022 · strength 0.46
  11. Kosuke Mima · 3 shared papers, 2022–2023 · strength 0.45
  12. Shigeki Nakagawa · 3 shared papers, 2022–2023 · strength 0.45
  13. Junpei Sasajima · 4 shared papers, 2018–2021 · strength 0.35
  14. Andrew Scott Liss · 2 shared papers, 2022–2025 · strength 0.35
  15. Jon Michael Harrison · 2 shared papers, 2022–2024 · strength 0.33
  16. Tatsunori Miyata · 2 shared papers, 2023 · strength 0.32
  17. Hideo Baba · 2 shared papers, 2022–2023 · strength 0.29
  18. Katsunori Imai · 2 shared papers, 2022–2023 · strength 0.29
  19. Junko Tanaka · 1 shared paper, 2025 · strength 0.24
  20. Takahide Yokoi · 1 shared paper, 2025 · strength 0.24
  21. Carlos F. Fernandez-del Castillo · 1 shared paper, 2024 · strength 0.22
  22. Susan Kuo · 1 shared paper, 2024 · strength 0.22
  23. Marco Ventin · 1 shared paper, 2024 · strength 0.22
  24. Motaz Qadan · 1 shared paper, 2024 · strength 0.22
  25. Cristina Rosa Ferrone · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.